Comparative Physical and Pharmacologic Characteristics of Iodine-131 and Yttrium-90: Implications for Radioimmunotherapy for Patients with Non-Hodgkin's Lymphoma

References

• Gallagher C.J., Gregory W.M., Jones A.E., et al. Follicular lymphoma: prognostic factors for response and survival. J. Clin. Oncol. 1986; 4: 1470–1480
   PubMed Web of Science ®Google Scholar
• Armitage J.O. Treatment of non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 328: 1023–1030
   PubMed Web of Science ®Google Scholar
• Horning S.J. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin. Oncol. 1993; 20: 75–88
   PubMed Web of Science ®Google Scholar
• Morrison V.A., Peterson B.A. High-dose therapy and transplantation in non-Hodgkin's lymphoma. Semin. Oncol. 1999; 26: 84–98
   PubMed Web of Science ®Google Scholar
• Appelbaum F.R., Sullivan K.M., Buckner C.D., et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J. Clin. Oncol. 1987; 5: 1340–1347
   PubMed Web of Science ®Google Scholar
• Liu S.Y., Press O.W. The potential for immunoconjugates in lymphoma therapy. Hematol. Oncol. Clin. N. Am. 1997; 11: 987–1006
   PubMed Web of Science ®Google Scholar
• Stashenko P., Nadler L.M., Hardy R., et al. Characterization of a human B lymphocyte-specific antigen. J. Immunol. 1980; 125: 1678–1685
   PubMed Web of Science ®Google Scholar
• Einfeld D.A., Brown J.P., Valentine M.A., et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 1988; 7: 711–717
   PubMed Web of Science ®Google Scholar
• Byrd J.C., Shinn C.A., Jansure J., et al. Campath-1H induces apoptosis in human chronic lymphocytic leukemia cells (CLL) in vitro independent of complement mediated lysis or Fcγ? receptor ligation [abstract]. Blood 1999; 94: 126a, Abstract 556
   Web of Science ®Google Scholar
• Byrd J.C., Shinn C.A., Pearson M.D., et al. Hu1D10 induces apoptosis in vitro in human chronic lymphocytic leukemia cells (CLL) independent of complement mediated lysis but requires Fcγ? receptor ligation [abstract]. Blood 1999; 94: 314a, Abstract 1405
   Web of Science ®Google Scholar
• Pearson M.D., Shinn C., Grever M.R., et al. Rituximab induces in vitro apoptosis in human chronic lymphocytic leukemia cells (CLL) independent of complement mediated lysis but requires Fcγ? receptor ligation [abstract]. Blood 1999; 94: 313b, Abstract 4626
   Web of Science ®Google Scholar
• Shan D., Ledbetter J.A., Press O.W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91: 1644–1652
   PubMed Web of Science ®Google Scholar
• Kolstad A., Tuck M.K., Kaminski M.S. Characterization of the apoptotic process initiated by ligation of CD20 by the mouse monoclonal antibody anti-B1 in the Burkitt's lymphoma cell line RAMOS [abstract]. Blood 1999; 94: 87a, Abstract 378
   PubMed Web of Science ®Google Scholar
• Kaminski M.S., Zasadny K.R., Francis I.R., et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol. 1996; 14: 1974–1981
   PubMed Web of Science ®Google Scholar
• Kaminski M.S., Estes J., Zasadny K.R., et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 1259–1266
   PubMed Web of Science ®Google Scholar
• Press O.W., Appelbaum F., Ledbetter J.A., et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987; 69: 584–591
   PubMed Web of Science ®Google Scholar
• McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Nourigat C., Badger C.C., Bernstein I.D. Treatment of lymphoma with radiolabeled antibody: elimination of tumor cells lacking target antigen. J. Natl Cancer Inst. 1990; 82: 47–50
   PubMed Web of Science ®Google Scholar
• Press O.W. Radiolabeled antibody therapy of B-cell lymphomas. Semin. Oncol. 1999; 26: 58–65
   PubMed Web of Science ®Google Scholar
• Wheldon T.E. The radiobiological basis of total body irradiation. Br. J. Radiol. 1997; 70: 1204–1207
   PubMed Web of Science ®Google Scholar
• Witzig T.E., White C.A., Gordon L.I., et al. Final results of a randomized controlled study of the Zevalin™ radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL [abstract]. Blood 2000; 96: 831a, Abstract 3591
   Web of Science ®Google Scholar
• Witzig T.E., White C.A., Flinn I.W., et al. Zevalin™ radioimmunotherapy of rituximab-refractory follicular non-Hodgkin's lymphoma [abstract]. Blood 2000; 96: 507a, Abstract 2183
   Web of Science ®Google Scholar
• Horning S.J., Lucas J.B., Younes A., et al. Iodine-131 tositumomab for non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with rituximab: results of a multi-center phase II study [abstract]. Blood 2000; 96: 508a, Abstract 2184
   Web of Science ®Google Scholar
• Sharkey R.M., Motta-Hennessy C., Pawlyk D., et al. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res. 1990; 50: 2330–2336
   PubMed Web of Science ®Google Scholar
• Press O.W., Appelbaum F.R., Eary J.F., . Radiolabeled antibody therapy of lymphomas. Important Advances in Oncology 1995, V.T. DeVita, S. Hellman, S.A. Rosenberg, et al. J. B. Lippincott Co, Philadelphia 1995; 157–171
   Google Scholar
• Knox S.J., Goris M.L., Trisler K., et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res. 1996; 2: 457–470
   PubMed Web of Science ®Google Scholar
• Behr T.M., Juweid M.E., Sharkey R.M., et al. Thyroid radiation doses during radioimmunotherapy of CEA-expressing tumours with 131I-labelled monoclonal antibodies. Nucl. Med. Commun. 1996; 17: 767–780
   PubMed Web of Science ®Google Scholar
• Zuckier L.S., Li Y., Chang C.J. Evaluation in a mouse model of a thyroid-blocking protocol for 131I antibody therapy (short communication). Cancer Biother. Radiopharm. 1998; 13: 457–460
   PubMed Web of Science ®Google Scholar
• Stewart J.S.W., Hird V., Snook D., et al. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry. Int. J. Cancer 1988; 3(Suppl. 3)71–76
   Google Scholar
• Comtois R., Theriault C., Del Vecchio P. Assessment of the efficacy of iodine-131 for thyroid ablation. J. Nucl. Med. 1993; 34: 1927–1930
   PubMed Web of Science ®Google Scholar
• Leung S.F., Law M.W., Ho S.K. Efficacy of low-dose iodine-131 ablation of post-operative thyroid remnants: a study of 69 cases. Br. J. Radiol. 1992; 65: 905–909
   PubMed Web of Science ®Google Scholar
• DeNardo G.L., DeNardo S.J., Lamborn K.R., et al. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother. Radiopharm. 1998; 13: 239–254
   PubMed Web of Science ®Google Scholar
• Press O.W., Farr A.G., Borroz K.I., et al. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res. 1989; 49: 4906–4912
   PubMed Web of Science ®Google Scholar
• Press O.W., Howell-Clark J., Anderson S., et al. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994; 83: 1390–1397
   PubMed Web of Science ®Google Scholar
• Press O.W., Shan D., Howell-Clark J., et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996; 56: 2123–2129
   PubMed Web of Science ®Google Scholar
• DeNardo G.L., DeNardo S.J., Miyao N.P., et al. Non-dehalogenation mechanisms for excretion of radioiodine after administration of labeled antibodies. Int. J. Biol. Markers 1988; 3: 1–9
   PubMedGoogle Scholar
• Colcher D. Centralized radiolabeling of antibodies for radioimmunotherapy. J. Nucl. Med. 1998; 39: 11s–13s
   PubMed Web of Science ®Google Scholar
• Juweid M.E., Stadtmauer E., Hajjar G., et al. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin. Cancer Res. 1999; 5: 3292s–3303s
   PubMed Web of Science ®Google Scholar
• Roberson P.L., Buchsbaum D.J., Heidorn D.B., et al. Three-dimensional tumor dosimetry for radioimmunotherapy using serial autoradiography. Int. J. Radiat. Oncol. Biol. Phys. 1992; 24: 329–334
   PubMed Web of Science ®Google Scholar
• Buchsbaum D.J., Lawrence T.S., Roberson P.L., et al. Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts. Int. J. Radiat. Oncol. Biol. Phys. 1993; 25: 629–638
   PubMed Web of Science ®Google Scholar
• O'Donoghue J.A., Bardies M., Wheldon T.E. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J. Nucl. Med. 1995; 36: 1902–1909
   PubMed Web of Science ®Google Scholar
• Illidge T., Honeychurch J., Vandersteen A., et al. Radioimmunotherapy in the pi-BCL1 B cell lymphoma model: efficacy depends on more than targeted irradiation alone. Cancer Biother. Radiopharm. 2000; 15: 581–591
   PubMed Web of Science ®Google Scholar
• O'Donnell R.T., DeNardo S.J., Miers L.A., et al. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts. Cancer Biother. Radiopharm. 1998; 13: 351–361
   PubMed Web of Science ®Google Scholar
• DeNardo G.L., O'Donnell R.T., Shen S., et al. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. J. Nucl. Med. 2000; 41: 952–958
   PubMed Web of Science ®Google Scholar
• DeNardo G.L., DeNardo S.J., Shen S., et al. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J. Nucl. Med. 1999; 40: 1317–1326
   PubMed Web of Science ®Google Scholar
• Witzig T.E., White C.A., Wiseman G.A., et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 1999; 17: 3793–3803
   PubMed Web of Science ®Google Scholar
• Wiseman G.A., White C.A., Stabin M., et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur. J. Nucl. Med. 2000; 27: 766–777
   PubMedGoogle Scholar
• Kaminski M.S., Estes J., Tuck M., et al. Iodine I 131 tositumomab therapy for previously untreated follicular lymphoma (FL) [abstract]. Proc. Am. Soc. Clin. Oncol. 2000; 19: 5a, Abstract 11
   Google Scholar
• Wahl R.L., Kroll S., Zasadny K.R., et al. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J. Nucl. Med. 1998; 39: 14s–20s
   PubMed Web of Science ®Google Scholar
• Vose J.M., Wahl R.L., Saleh M., et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 2000; 18: 1316–1323
   PubMed Web of Science ®Google Scholar
• Shen S., DeNardo G.L., Yuan A., et al. Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. J. Nucl. Med. 1994; 35: 1381–1389
   PubMed Web of Science ®Google Scholar
• Hnatowich D.J., Virzi F., Doherty P.W. DTPA-coupled antibodies labeled with yttrium-90. J. Nucl. Med. 1985; 26: 503–509
   PubMed Web of Science ®Google Scholar
• Carrasquillo J.A., Kramer B., Fleisher T., et al. In-111 versus Y-90 T101 biodistribution in patients with hematopoietic malignancies [abstract]. J. Nucl. Med. 1991; 32: 970, Abstract 260
   Google Scholar
• Carrasquillo J.A., White J.D., Paik C.H., et al. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. J. Nucl. Med. 1999; 40: 268–276
   PubMed Web of Science ®Google Scholar
• DeNardo G.L., Kroger L.A., DeNardo S.J., et al. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer 1994; 73: 1012–1022
   PubMed Web of Science ®Google Scholar
• Nuclear Regulatory Commission Web site. The Code of Federal Regulations: Title 10-Energy. Available at: http://www.nrc.gov/NCR/CFR/FRONT/title10.html (accessed September 7, 2001).
   Google Scholar
• Nuclear Regulatory Commission Web site. Regulatory Guide 8.39: release of patients administered radioactive materials. Available at: http://www.nrc.gov/NRC/RG/O8/index.html (accessed September 7, 2001).
   Google Scholar
• Siegel J.A. Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-B1 therapy. J. Nucl. Med. 1998; 39: 28s–33s
   PubMed Web of Science ®Google Scholar
• Gates V.L., Carey J.E., Siegel J.A., et al. Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy. J. Nucl. Med. 1998; 39: 1230–1236
   PubMed Web of Science ®Google Scholar
• Rutar F.J., Augustine S.C., Jacobson D.A., et al. Radiation doses received by non-occupational caregivers exposed to NHL patients receiving radioimmunotherapy [abstract]. Blood 1999; 94: 90a, Abstract 395
   Web of Science ®Google Scholar
• Barrington S.F., Kettle A.G., O'Doherty M.J., et al. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. Eur. J. Nucl. Med. 1996; 23: 123–130
   PubMedGoogle Scholar
• Grigsby P.W., Siegel B.A., Baker S., et al. Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma. J. Am. Med. Assoc. 2000; 283: 2272–2274
   Web of Science ®Google Scholar
• Zanzonico P.B. Radiation dose to patients and relatives incident to 131I therapy. Thyroid 1997; 7: 199–204
   PubMed Web of Science ®Google Scholar
• Siegel, J.A., Kroll, S., Regan, D.; et al. A practical methodology for patient release following tositumomab and iodine I 131 tositumomab therapy, submitted.
   Google Scholar
• Rutar F.J., Augustine S.C., Colcher D., et al. Outpatient treatment with (131) I-anti-B1 antibody: radiation exposure to family members. J. Nucl. Med. 2001; 42: 907–915
   PubMed Web of Science ®Google Scholar
• DeNardo G.L., Lamborn K.R., Goldstein D.S., et al. Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Cancer 1997; 80: 2706–2711
   PubMed Web of Science ®Google Scholar
• Vose J.M., Colcher D., Gobar L., et al. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leuk. Lymphoma 2000; 38: 91–101
   PubMed Web of Science ®Google Scholar